Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESTORE: STR001 in Sudden Sensorineural Hearing Loss
NCT03331627Phase 3Completed
- Sponsor
- Strekin AG
- Start
- Feb 2018
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of pioglitazone in sudden sensorineural hearing loss (SSHL) (3 arms), sponsored by Strekin AG. Primary endpoint: Absolute hearing improvement after 12 weeks. Started Feb 2018; status: completed.
02
Drugs
pioglitazone
03
Conditions
sudden sensorineural hearing loss (SSHL)
Beyond the preview
Go deeper on NCT03331627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03331627.